The attractiveness of Sirt6 as a therapeutic target had been reported in the conditions of cardiac fibrosis, renal fibrosis, and idiopathic pulmonary fibrosis (Cai et al. 2022; Zhang et al. 2019). Here, SIRT6 is linked to idiopathic pulmonary fibrosis.